Dr. Reddy's Laboratories has introduced the OTC Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S. market, offering relief from itchy eyes due to common allergens. This first-to-market launch reinforces the company's growing presence
Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration for its supplemental Abbreviated New Drug Application (sANDA) for Bosutinib tablets, 400 mg, strengthening the company’s US oncology generics market pre...
The World Health Organization today released WHO HIV clinical guidelines that set a new direction for HIV treatment, prevention, and tuberculosis care, reflecting major scientific progress since the last update in 2021...
Abbott launches Libre Assist at CES 2026, a smart Libre app feature using AI and CGM data to guide meal choices and predict glucose impact for people with diabetes.
.jpeg)
Dr Reddy’s launches Hevaxin, India’s only DCGI-approved hepatitis E vaccine, offering long-term immunity and supporting national efforts to reduce liver disease burden.
AstraZeneca today announced positive phase III clinical data for baxdrostat, an investigational oral therapy being developed for patients with uncontrolled or resistant hypertension. The results strengthen baxdrostat’s position as a potential...
Health ministry bans oral nimesulide above 100 mg for human use after DTAB and ICMR review, citing safety risks, second-line therapy use, and safer drug alternatives.
.jpeg)
Strides Pharma shares dip after USFDA issues Form 483 observations at its US facility, though the company says issues are procedural with no supply impact.
India strengthens pharma regulation in 2025 with WHO benchmarking, ONDLS solvent tracking, QR codes on critical drugs, and anti-dumping probes to boost safety and compliance.
AstraZeneca has announced that its LATIFY phase III trial didn't work out as planned. The trial was testing ceralasertib mixed with Imfinzi (durvalumab) against the usual docetaxel treatment for patients with non-small cell lung cancer (NSCLC) that h
, CDSCO.jpg)